NEW YORK, Oct. 11, 2016 /PRNewswire/ -- Erythropoietin drugs are protein therapeutics, which is used to treat various types of anaemia. These drugs play a significant role in treating CKD related anaemia and cancer related anaemia. Since its inception, the erythropoietin drugs market has witnessed various technological advancements, which have resulted in development of more effective and long acting EPO drugs.
Launch of biosimilars in the erythropoietin market has increased its affordability. European region is the largest market for erythropoietin biosimilar, which makes it a major market for over all erythropoietin drugs as well. As per RNCOS report "European Erythropoietin Market Outlook 2022", the market of Europe was valued at US$ 1.4 Billion in 2015. This report provides a detailed analysis of the current and future market scenario of the European erythropoietin market. The report highlights biosimilar erythropoietin at various stages of clinical development. In addition, the report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth.
Based on segment, the report sub-divides the market into biologics and biosimilar. Currently, biologics hold major share in the European market. However, biosimilar market is poised to witness the highest growth due to their cost effectiveness. Based on country, the report segments the market into Germany, France, UK, Italy, and Spain. The report provides detailed analysis of each country. Moreover, the report also provides the market for various types of EPO (alpha, beta, and darbepoetin alpha amongst other) for each country. Furthermore, the report covers the prevalence and incidences of CKD and cancer for each country under application segmentation. Additionally, the report also provides the patent analysis and pipeline analysis of erythropoietin market.
The last section of the report discusses about the prominent players in European erythropoietin market. A brief business overview and financial information about each of these players has been provided along with their product portfolios. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the European erythropoietin market.
Read the full report: http://www.reportlinker.com/p04213081-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/european-erythropoietin-market-outlook-2022-300343218.html